2023 World Conference on Lung Cancer (Posters)-EP12.01. A Study of Aumolertinib Monotherapy or Combination Treated EGFR-mutated NSCLC Patients with Symptomatic Brain Metastases

EP12.01. A Study of Aumolertinib Monotherapy or Combination Treated EGFR-mutated NSCLC Patients with Symptomatic Brain Metastases - PDF(Slides)

Back to course

Pdf Summary

A study was conducted to evaluate the efficacy and safety of Aumolertinib, a third-generation EGFR-TKI, in patients with symptomatic brain metastases. While previous clinical trials excluded patients with both EGFR mutations and symptomatic brain metastases, this study aimed to examine the benefits of EGFR-TKI in this specific patient population. The study included patients with confirmed EGFR-mutated NSCLC and symptomatic brain metastases. The primary endpoint was progression-free survival (PFS), and secondary endpoints included objective response rate (ORR), disease control rate (DCR), overall survival (OS), and safety.<br /><br />The study included 11 patients who received first-line therapy and 22 patients who received subsequent therapy. The results showed that Aumolertinib monotherapy or combination therapy demonstrated significant efficacy in prolonging survival time in patients with symptomatic brain metastases. The 12- and 24-month PFS rates were 81.8% and 63.6%, respectively. The 12- and 24-month OS rates were 90.9% and 81.8%. In terms of neurological symptomatic response, all patients showed improvement during first-line therapy, and 90.9% showed improvement during subsequent therapy. The majority of adverse events were categorized as Grade 1-2, with limited Grade 3 adverse events.<br /><br />Based on these findings, the study concludes that Aumolertinib monotherapy or combination therapy can prolong survival and improve neurological symptoms in EGFR-mutated NSCLC patients with symptomatic brain metastases. The study suggests that EGFR-TKI treatment can provide substantial benefits in this specific patient population, similar to patients without brain metastases. However, further investigations with larger samples are needed to confirm the efficacy of EGFR-TKI in patients with symptomatic brain metastases. The study acknowledges the patients, their families, investigators, study coordinators, and supporting staff for their contributions.

Asset Subtitle

Xiaojuan Zhang

Meta Tag

Speaker Xiaojuan Zhang

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

Aumolertinib

third-generation EGFR-TKI

symptomatic brain metastases

EGFR mutations

NSCLC

progression-free survival

objective response rate

disease control rate

overall survival

safety